

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/17	A1	(11) International Publication Number: WO 99/53942 (43) International Publication Date: 28 October 1999 (28.10.99)
(21) International Application Number: PCT/US99/08793 (22) International Filing Date: 21 April 1999 (21.04.99) (30) Priority Data: 09/064,832 23 April 1998 (23.04.98) US (71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US). (72) Inventors: SIMONET, Scott; 2293 Watertown Court, Thou- sand Oaks, CA 91360 (US). SAROSI, Ildiko; 587F North Ventu Park Road #139, Newbury Park, CA 91320 (US). (74) Agents: ODRE, Steven, M. et al.; Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: COMPOSITIONS COMPRISING OSTEOPROTEGERIN FOR THE PREVENTION AND TREATMENT OF CARDIO- VASCULAR DISEASES (57) Abstract Methods and compositions for the prevention and treatment of cardiovascular disease are described. Administration of osteoprotegerin (OPG) in a pharmaceutical composition prevents and treats atherosclerosis and associated cardiovascular diseases.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

COMPOSITIONS AND METHODS FOR THE
PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

5 Field of the Invention

The invention relates to treatment of cardiovascular diseases. More particularly, the invention involves use of osteoprotegerin (OPG) to treat and prevent cardiovascular diseases associated with occlusion and calcification of blood vessels, such as atherosclerosis.

Background of the Invention

15 Development and maintenance of the mammalian skeleton involves the regulation and interaction of its component cell types (Erlebacher et al. Cell 80, 371-380 (1995); Marks, Acta Med Dent Helv 2, 141-157 (1997)). Major contributors to skeletal architecture include chondrocytes which form cartilage, osteoblasts which synthesize and deposit bone matrix, and osteoclasts which resorb bone. Chondrocytes are derived from mesenchymal cells and function to generate an initial cartilage template required for endochondral bone formation. Osteoblasts, derived from mesenchymal osteoprogenitor cells, are located on the surface of bone where they synthesize, transport and arrange the matrix proteins. Osteoclasts are derived from granulocyte-monocyte precursors present in the hematopoietic marrow (Roodman, Endocrine Rev. 17, 308-332 (1996); Mundy, J. Bone Min. Res. 8, S505-S510 (1993); Manolagas and Jilka New Eng. J. Med. 332, 305-311 (1995)). After establishing a tight adherence to the bone surface, osteoclasts form resorption zones that are acidified by a specialized structure known as the ruffled border. The ruffled border functions as a

- 2 -

secretory conduit where protons and acid proteases are secreted which decalcify and then digest bone matrix. During the process of osteoclast mediated resorption, it is thought that protein factors are elaborated that act as signaling molecules to initiate bone renewal by osteoblasts. Osteoblasts, in turn, can influence osteoclast function through the expression of soluble or membrane bound regulators (Takahashi et al. Endocrinology 123, 2600-2602 (1988)). The coupling between osteoblast and osteoclast functions is critical for skeletal modeling, remodeling, and repair (Mundy, J. Cell Biochem. 53, 296-300 (1993); Mundy et al. Bone 17, 71S-75S F(1995)).

Postmenopausal osteoporosis, the most common bone disease in the developed world, has been causally linked to estrogen loss (for review, see Pacifici, J. Bone Min. Res. 11, 1043-1051 (1996)). Postmenopausal bone loss can be attributed to loss of regulatory control exerted by estrogen on the production of cytokines and other factors that regulate osteoclast development. The resultant shift in the balance of osteoclast and osteoblast activity favors a net loss of bone mass ultimately leading to osteoporosis.

Osteoporosis in human populations has been associated with a higher incidence of arterial calcification, a component of many atherosclerotic lesions (Parhami and Demer, Curr. Opin. Lipidology 8, 312-314 (1997); Banks et al. Eur. J. Clin. Invest. 24, 813-817 (1994); Parhami et al. Arterioscler. Thromb. Vasc. Biol. 17, 680-687 (1997)). Common factors may underlay the pathogenesis of these two diseases. Indeed some arterial calcium mineral deposits appear identical to fully formed lamellar bone, including trabeculae, lacunae, and islands of marrow (Haust and Geer, Am. J. Pathol. 60, 329-346 (1970); Bunting, J. Exp. Med. 8, 365-376 (1906)). Furthermore, calcified

- 3 -

arteries have been shown to express several bone matrix proteins, including collagen Type I, matrix GLA protein, osteocalcin, osteonectin and bone morphogenetic protein type 2 (Bostrom et al. J. Clin. Invest. 91, 1800-1809 (1993); O'Brien et al. Circulation 92, 2163-2168 (1995); Giachelli et al. J. Clin. Invest. 92, 1686-1696 (1993); Bostrom et al. Am. J. Cardiol. 75, 88B-91B (1995)). These findings have lead to speculation that arterial calcification is an organized, regulated process with cellular and molecular mechanisms similar to organized bone formation (Demer, Circulation 92, 2029-2032 (1995); Parhami et al. J. Atheroscler. Thromb. 3, 90-94 (1996)).

Osteoprotegerin (OPG), a recently identified member of the tumor necrosis factor receptor gene superfamily, is a secreted factor that inhibits osteoclast development both in vitro and in vivo (Simonet et al. Cell 89, 309-319 (1997); PCT Application No. US96/20621 (WO97/23614) which is hereby incorporated by reference). Transgenic mice overexpressing OPG in the liver, have high levels of OPG protein in their systemic circulation and exhibit a marked increase in bone density (osteopetrosis). In normal mouse embryos, OPG has been localized within cartilage rudiments of developing bones, as well as in the small intestine and the muscular wall of the aorta and several major arteries.

Given the strong correlation between the occurrence of osteoporosis and the onset of conditions which could lead to cardiovascular disease, particularly disease characterized by arterial calcification, and the similarities in the processes for depositing calcium in bone and along the interior of arterial walls, it is an object of the invention to develop pharmaceutical compositions and methods for the

- 4 -

concurrent prevention and treatment of osteoporosis and cardiovascular disease. Development of a single therapeutic for the prevention and treatment of both conditions would greatly enhance the longevity and quality of life of affected patients, by reducing the risk of crippling and possibly fatal bone fractures and, at the same time, preventing or retarding conditions which could lead to hypertension, ischemia, heart attacks, and stroke.

10 Surprisingly, it has been found that loss of OPG in an OPG knockout animal results in calcification of the aorta and renal arteries, which are sites of endogenous OPG expression in normal animals. These findings implicate OPG in the regulation of
15 pathological calcification of arteries such that, when circulating OPG is absent or present at low levels, accumulation of calcium deposits on arterial walls is greatly accelerated. The presence of normal or above normal levels of OPG (such as in transgenic mice
20 expressing OPG) are not associated with vascular calcification.

Summary of the Invention

25 The present invention relates to methods and compositions for treating or preventing cardiovascular diseases. The methods comprise administration of a therapeutically effective amount of OPG wherein said amount is sufficient to treat or prevent a
30 cardiovascular disease.

The present invention also relates to OPG compositions useful for treating or preventing cardiovascular disease. OPG compositions are typically pharmaceutically acceptable mixtures suitable for a
35 variety of routes of administration.

- 5 -

Description of the Figures

Figure 1. In situ hybridization analysis of OPG expression on frozen sections of E17 rat embryo heart (Panels A and B) and adult rat renal artery (Panels C and D). On light microscopy the presence of OPG mRNA is seen as dark grains over the aorta, the background stain is Methyl green (A). On dark field microscopy of the same specimen strong OPG mRNA expression is seen over the ribs and the aorta (B). Somewhat weaker signal is present in the renal artery of the adult rat on light and dark field microscopy (C and D, respectively).

15

Figure 2. In situ hybridization analysis of OPG expression on formalin fixed sections of E20.5 rat embryo. On light microscopy the presence of OPG RNA is seen as dark grains over the aorta, the background stain is hemalaun (Panels A, B and D). On dark field microscopy of the same specimen strong OPG mRNA expression is seen over the aorta. (Panels C and E) E20.5 rat embryo, 1/2X magnification, section stained with hematoxylin and eosin (A); 4X, H and E (B); 4X (C); 10X, H and E (D); 10X (E).

25

Figure 3. Arterial calcification in male OPG^{-/-} mice. OPG^{-/-} mouse #26 has calcification and intimal proliferation in the descending aorta (Panel A) and renal artery (Panel B). OPG^{-/-} mouse #38 has pronounced calcification in the bulb of the aorta (Panel C). The massive subintimal proliferation could be the consequence of a dissection of the wall of the aorta and subsequent bleeding into the space between the layers of the aortic wall. Aneurysm formation and dissection of the wall of the aorta is a common

35

- 6 -

complication of severe arteriosclerosis. There is severe calcification as well as intimal and medial proliferation in the renal artery (Panel D).

5 Figure 4. Arterial calcification in female OPG^{-/-} mice. The aorta of wild type mouse #82 is shown as negative control (Panel A). OPG^{-/-} mouse #86 has several calcified lesions in the abdominal aorta (Panel B). OPG^{-/-} mouse #77 has several calcified lesions in
10 the abdominal aorta (Panel D) and in several smaller branches (Panel C).

Detailed Description of the Invention

15 Homozygous OPG^{-/-} knockout mice displayed severe osteoporosis when analyzed by whole body X-ray and by histology. Characterization of bone structure from OPG knockout mice is described in co-pending and co-owned U.S. Serial No. 08/943,687 hereby incorporated
20 by reference. It was unexpectedly found that both male and female homozygous OPG knockout mice also exhibited marked calcification and intimal proliferation in the aorta and renal artery. These arterial changes were not observed in heterozygous OPG^{+/-} knockout mice, in
25 normal OPG^{+/+} mice, or in transgenic mice exhibiting elevated circulating levels of OPG. OPG^{+/-} mice show bone loss by 6 months of age. Taken together, these observations indicated a role for OPG in preventing or reducing arterial calcification and lessening the risk
30 of atherosclerosis.

OPG polypeptides

 OPG polypeptides of the invention include human OPG or a derivative, truncation, or chemically
35 modified form thereof having at least one of the

- 7 -

biological activities of OPG. The amino acid sequence of human OPG is shown in SEQ ID NO:1 and SEQ ID NO: 2. A derivative of OPG refers to a polypeptide having an addition, deletion, insertion or substitution of one or more amino acids such that the resulting polypeptide has at least one of the biological activities of OPG. The biological activities of OPG include, but are not limited to, activities involving bone metabolism. In one embodiment, OPG polypeptides have anti-resorptive activity on bone. In another embodiment, OPG polypeptides have activity in reducing or eliminating calcification of arterial walls.

OPG polypeptides will be mature OPG polypeptides having the amino terminal leader sequence of 21 amino acids removed. Polypeptides include residues 22-401 as shown in SEQ ID NO:1 and derivatives thereof having deletions or carboxy-terminal truncations of part or all of amino acids residues 180-401 of OPG; one or more amino acid changes in residues 180-401; deletion of part or all of a cysteine-rich domain of OPG, in particular deletion of the distal (carboxy-terminal) cysteine-rich domain; and one or more amino acid changes in a cysteine-rich domain, in particular in the distal (carboxy-terminal) cysteine-rich domain. In one embodiment, OPG has up to about 216 amino acids deleted from the carboxy terminus. In another embodiment, OPG has up to about 10 amino acids deleted from the mature amino terminus (wherein the mature amino terminus is at residue 22) and, optionally, has up to about 216 amino acids deleted from the carboxy terminus.

Additional OPG polypeptides encompassed by the invention include the following: human [22-180]-Fc fusion, human [22-201]-Fc fusion, human [22-401]-Fc fusion, human [22-185]-Fc fusion, and human [22-194]-Fc fusion. These polypeptides are produced in mammalian

- 8 -

host cells, such as CHO or 293 cells, Additional OPG polypeptides encompassed by the invention which are expressed in procaryotic host cells include the following: human met[22-401], met Fc-human [22-401] fusion (Fc region is fused at the amino terminus of the full-length OPG coding sequence) human met[22-401]-Fc fusion (Fc region fused at the carboxy terminus to the full-length OPG sequence), met Fc-human [22-201] fusion, human met[22-201]-Fc fusion, met-Fc-human [22-194], human met[22-194]-Fc, human met[27-401], human met[22-185], human met[22-189], human met[22-194], human met[22-194] (P25A), human met [22-194] (P26A), human met[27-185], human met[27-189], human met[27-194], human met-arg-gly-ser-(his)₆ [22-401], human met-lys [22-401], human met-(lys)₃-[22-401], human met[22-401]-Fc (P25A), human met[22-401] (P25A), human met[22-401] (P26A), human met[22-401] (P26D) It is understood that the above OPG polypeptides produced in procaryotic host cells have an amino-terminal methionine residue, if such a residue is not indicated. In specific examples, OPG-Fc fusion polypeptides were produced using a 227 amino acid region of human IgG₁-γ1 was used having the sequence as shown in Ellison et al. (Nuc. Acids Res. 10, 4071-4079 (1982)). However, variants of the Fc region of human IgG may also be used.

Analysis of the biological activity of carboxy-terminal OPG truncations fused to the Fc region of human IgG₁ indicates that a portion of OPG of about 164 amino acids is required for activity. This region encompasses amino acids 22-185, preferably those in SEQ ID NO:1 and comprises four cysteine-rich domains characteristic of the cysteine-rich domains of tumor necrosis factor receptor (TNFR) extracellular domains.

- 9 -

Using the homology between the cysteine rich domains of OPG and TNFR family members, a three-dimensional model of OPG was generated based upon the known crystal structure of the extracellular domain of TNFR-I (see WO97/23614). This model was used to identify those residues within OPG which may be important for biological activity. Cysteine residues that are involved in maintaining the structure of the four cysteine-rich domains were identified. The following disulfide bonds were identified in the model: Domain 1: cys41 to cys54, cys44 to cys62, tyr23 and his 66 may act to stabilize the structure of this domain; Domain 2: cys65 to cys80, cys83 to cys98, cys87 to cys105; Domain 3: cys107 to cys118, cys124 to cys142; Domain 4: cys145 to cys160, cys166 to cys185. Residues were also identified which were in close proximity to TNF β as shown in Figures 11 and 12A-12B of WO97/23614. In this model, it is assumed that OPG binds to a corresponding ligand; TNF β was used as a model ligand to simulate the interaction of OPG with its ligand. Based upon this modeling, the following residues in OPG may be important for ligand binding: glu34, lys43, pro66 to gln91 (in particular, pro66, his68, tyr69, tyr70, thr71, asp72, ser73, his76, ser77, asp78, glu79, leu81, tyr82, pro85, val86, lys88, glu90 and gln91), glu153 and ser155.

Alterations in these amino acid residues, either singly or in combination, may alter the biological activity of OPG. For example, changes in specific cysteine residues may alter the structure of individual cysteine-rich domains, whereas changes in residues important for ligand binding may affect physical interactions of OPG with ligand. Structural models can aid in identifying analogs which have more desirable properties, such as enhanced biological

- 10 -

activity, greater stability, or greater ease of formulation.

Modifications of OPG polypeptides are encompassed by the invention and include post-translational modifications (e.g., N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Further modifications of OPG include OPG chimeric or fusion proteins wherein OPG is fused to a heterologous amino acid sequence. The heterologous sequence may be any sequence which allows the resulting fusion protein to retain the activity of OPG. The heterologous sequences include for example, immunoglobulin fusions, such as Fc fusions, which may aid in purification of the protein. A heterologous sequence which promotes association of OPG monomers to form dimers, trimers and other higher multimeric forms is preferred.

In one embodiment, an OPG chimeric protein comprises a fusion of a truncated OPG polypeptide with an Fc region of human IgG. Truncations of OPG may occur at the amino or carboxy termini, or both, and preferably are truncations of up to about 216 amino acids from the carboxy terminus at residue 401. Fusion to an Fc region may occur between the carboxy terminus of an Fc and the amino terminus of an OPG truncated polypeptide, or alternatively between the amino terminus of an Fc region and the carboxy terminus of an OPG truncated polypeptide. Examples of truncated OPG

- 11 -

polypeptides fused to an Fc region include residues 22-185, 22-189, 22-194 or 22-201 such as those shown in SEQ ID NO:1 or variants thereof.

5 The polypeptides of the invention are isolated and purified from other polypeptides present in tissues, cell lines and transformed host cells expressing OPG, or purified from components in cell cultures containing the secreted protein. In one
10 embodiment, the polypeptide is free from association with other human proteins, such as the expression product of a bacterial host cell.

 Also provided by the invention are chemically
15 modified derivatives of OPG which may provide additional advantages such as increasing stability and circulating time of the polypeptide, or decreasing immunogenicity (see U.S. Patent No. 4,179,337). The chemical moieties for derivitization may be selected
20 from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined
25 positions within the molecule and may include one, two, three or more attached chemical moieties.

 The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about
30 1kDa and about 100kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic
35 profile (e.g., the duration of sustained release desired, the effects, if any on biological activity,

- 12 -

the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

5 The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, e.g. EP 401 384 herein incorporated by reference (coupling PEG to G-CSF), see also Malik et al., Exp. Hematol. 20: 1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecule(s). Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

 The invention also provides for OPG selectively chemically modified at the amino terminus. Using polyethylene glycol as an illustration of the present compositions, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (or peptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-

- 13 -

terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective N-terminal chemically modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

The invention also provides for an OPG multimer comprising OPG monomers. OPG appears to be active as a multimer (e.g, dimer, trimer or a higher number of monomers). Preferably, OPG multimers are dimers or trimers. OPG multimers may comprise monomers having the amino acid sequence of OPG sufficient to promote multimer formation or may comprise monomers having heterologous sequences such as an antibody Fc region. Analysis of carboxy-terminal deletions of OPG suggest that at least a portion of the region 186-401 is involved in association of OPG polypeptides. Substitution of part or all of the region of OPG amino acids 186-401 with an amino acid sequence capable of self-association is also encompassed by the invention. Alternatively, OPG polypeptides or derivatives thereof may be modified to form dimers or multimers by site directed mutagenesis to create unpaired cysteine residues for interchain disulfide bond formation, by photochemical crosslinking, such as exposure to ultraviolet light, or by chemical crosslinking with

- 14 -

bifunctional linker molecules such as bifunctional polyethylene glycol and the like. In one embodiment, OPG multimers are formed by covalent linkage of OPG monomers lacking part or all of the region 186-401 such that association of OPG monomers occurs largely through
5 modification with the linking group.

OPG multimers may be prepared by various chemical crosslinking procedures. OPG monomers may be chemically linked in any fashion that retains or
10 enhances the biological activity of OPG. A variety of chemical crosslinkers may be used depending upon which properties of the protein dimer are desired. For example, crosslinkers may be short and relatively rigid or longer and more flexible, may be biologically
15 reversible, and may provide reduced immunogenicity or longer pharmacokinetic half-life.

OPG molecules are linked through the amino terminus by a two step procedure wherein OPG is chemically modified at the amino terminus to introduce
20 a protected thiol, which after purification is deprotected and used as a point of attachment for site-specific conjugation through a variety of crosslinkers with a second OPG molecule. Amino-terminal crosslinks include, but are not limited to, a disulfide bond,
25 thioether linkages using short-chain, bis-functional aliphatic crosslinkers, and thioether linkages to variable length, bifunctional polyethylene glycol crosslinkers (PEG "dumbbells"). Also encompassed by PEG dumbbell synthesis of OPG dimers is a byproduct of
30 such synthesis, termed a "monobell". An OPG monobell consists of a monomer coupled to a linear bifunctional PEG with a free polymer terminus. Alternatively, OPG may be crosslinked directly through a variety of amine specific homobifunctional crosslinking techniques which
35 include reagents such as: diethylenetriaminepentaacetic dianhydride (DTPA), p-benzoquinone (pBQ) or

- 15 -

bis(sulfosuccinimidyl) suberate (BS³) as well as others known in the art. It is also possible to thiolate OPG directly with reagents such as iminothiolane in the presence of a variety of bifunctional, thiol specific crosslinkers, such as PEG bismaleimide, and achieve dimerization and/or dumbbells in a one step process.

OPG multimers may also be formed by linking OPG monomers with peptides of varying length. The peptides are chosen to have an amino acid sequence and composition to act as flexible linkers between OPG monomers. Peptide linkers may join monomers in a head-to-head manner (N-terminal to N-terminal or C-terminal to C-terminal) or a head-to-tail manner (N-terminal to C-terminal). Peptide linkers will preferably be about 15-60 amino acids in length.

A method for the purification of OPG from natural sources and from transfected host cells is also included. The purification process may employ one or more standard protein purification steps in an appropriate order to obtain purified protein. The chromatography steps can include ion exchange, gel filtration, hydrophobic interaction, reverse phase, chromatofocusing, affinity chromatography employing an anti-OPG antibody or biotin-streptavidin affinity complex and the like.

Nucleic Acids

Nucleic acid molecules encoding OPG polypeptides of the invention are also provided. The nucleic acid molecules are selected from the following:

- a) the nucleic acid sequence as shown in SEQ ID NO:1 or complementary strand thereof;
- b) the nucleic acids which hybridize under stringent conditions with the polypeptide-encoding region in SEQ ID NO:1; and

- 16 -

c) the nucleic acid sequences which are degenerate to the sequences in (a) and (b).

Conditions for hybridization are generally of high stringency such as 5xSSC, 50% formamide and 42°C or the equivalent which may be readily obtained by adjusting salt and organic solvent concentrations and temperature. For example, conditions of equivalent stringency may also be used by increasing the temperature of the hybridization or washing step (to a range of 50°-65°C) and decreasing the salt concentration (to a range of 1 to 0.2 x SSC) while omitting organic solvent. Hybridization conditions for nucleic acids are described in further detail in Sambrook et al. Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989).

The length of hybridizing nucleic acids of the invention may be variable since hybridization may occur in part or all of the polypeptide-encoding region as shown in SEQ ID NO: 1 and may also occur in adjacent noncoding regions. Hybridizing nucleic acids may be shorter or longer in length than the complementary sequence shown in SEQ ID NO: 1. Truncated or extended nucleic acids which hybridize to SEQ ID NO: 1 may retain one or more of the biological properties of OPG, such as anti-resorptive activity on bone or protection against arterial calcification. The hybridizing nucleic acids may also include adjacent noncoding regions which are 5' and/or 3' to the OPG coding region. The noncoding regions include regulatory regions involved in OPG expression, such as promoters, enhance, translational initiation sites, transcription termination sites and the like.

- 17 -

Also provided by the invention are derivatives of the nucleic acid sequences as shown in SEQ ID NO:1. As used herein, derivatives include nucleic acid sequences having addition, substitution, insertion or deletion of one or more residues such that the resulting sequences encode polypeptides having one or more amino acid residues which have been added, deleted, inserted or substituted and the resulting polypeptide has the activity of OPG, such as anti-resorptive activity on bone or protection against arterial calcification. The nucleic acid derivatives may be naturally occurring, such as by splice variation or polymorphism, or may be constructed using site-directed mutagenesis techniques available to the skilled worker. One example of a naturally occurring variant of OPG is a nucleic acid encoding a lys to asn change at residue 3 within the leader sequence (see W097/23614). It is anticipated that nucleic acid derivatives will encode amino acid changes in regions of the molecule which are least likely to disrupt biological activity.

In one embodiment, derivatives of OPG include nucleic acids encoding truncated forms of full-length OPG (full-length OPG encompasses residues 22 to 401 of SEQ ID NO:1) having one or more amino acids deleted from the carboxy terminus. Nucleic acids encoding OPG may have up to about 216 amino acids deleted from the carboxy terminus. Optionally, an antibody Fc region may extend from the new carboxy terminus to yield a biologically active OPG-Fc fusion polypeptide, or an Fc region may extend from the amino terminus of the truncated OPG. In preferred embodiments, nucleic acids encode OPG having the amino acid sequence from residues 22-185, 22-189, 22-194 or 22-201 (using numbering in SEQ ID NO:1) and optionally, encoding an Fc region of human IgG.

- 18 -

Also included are nucleic acids encoding truncated forms of OPG having one or more amino acids deleted from the amino terminus. Truncated forms include those lacking part or all the 21 amino acids comprising the leader sequence. Mature OPG lacks all of the 21 amino acid leader sequence. Additionally, the invention provides for nucleic acids encoding OPG having from 1 to 10 amino acids deleted from the mature amino terminus (at residue 22) and, optionally, having from 1 to 216 amino acids deleted from the carboxy terminus (at residue 401). Optionally, the nucleic acids may encode a methionine residue at the amino terminus.

Examples of the nucleic acids of the invention include cDNA, genomic DNA, synthetic DNA and RNA. cDNA is obtained from libraries prepared from mRNA isolated from various tissues expressing OPG. In humans, tissue sources for OPG include kidney, liver, placenta and heart. Genomic DNA encoding OPG is obtained from genomic libraries which are commercially available from a variety of species. Synthetic DNA is obtained by chemical synthesis of overlapping oligonucleotide fragments followed by assembly of the fragments to reconstitute part or all of the coding region and flanking sequences (see U.S. Patent No. 4,695,623 describing the chemical synthesis of interferon genes). RNA is obtained most easily by procaryotic expression vectors which direct high-level synthesis of mRNA, such as vectors using T7 promoters and RNA polymerase.

Vectors and Host Cells

Expression vectors containing nucleic acid sequences encoding OPG, host cells transformed with said vectors and methods for the production of OPG are also provided by the invention. An overview of

- 19 -

expression of recombinant proteins is found in Methods of Enzymology v. 185, Goeddel, D.V. ed. Academic Press (1990).

Host cells for the production of OPG include
5 procaryotic host cells, such as E. coli, yeast, plant,
insect and mammalian host cells. E. coli strains such
as HB101 or JM101 are suitable for expression.
Preferred mammalian host cells include COS, CHOd-, 293,
CV-1, 3T3, baby hamster kidney (BHK) cells and others.
10 Mammalian host cells are preferred when post-
translational modifications, such as glycosylation and
polypeptide processing, are important for OPG activity.
Mammalian expression allows for the production of
secreted polypeptides which may be recovered from the
15 growth medium.

Vectors for the expression of OPG contain at
a minimum sequences required for vector propagation and
for expression of the cloned insert. These sequences
include a replication origin, selection marker,
20 promoter, ribosome binding site, enhancer sequences,
RNA splice sites and transcription termination site.
Vectors suitable for expression in the aforementioned
host cells are readily available and the nucleic acids
of the invention are inserted into the vectors using
25 standard recombinant DNA techniques. Vectors for
tissue-specific expression of OPG are also included.
Such vectors include promoters which function
specifically in liver, kidney or other organs for
production in mice, and viral vectors for the
30 expression of OPG in targeted human cells.

Using an appropriate host-vector system, OPG
is produced recombinantly by culturing a host cell
transformed with an expression vector containing
nucleic acid sequences encoding OPG under conditions
35 such that OPG is produced, and isolating the product of
expression. OPG is produced in the supernatant of

- 20 -

transfected mammalian cells or in inclusion bodies of transformed bacterial host cells. OPG so produced may be purified by procedures known to one skilled in the art as described below. The expression of OPG in
5 mammalian and bacterial host systems is described in WO97/23614. Expression vectors for mammalian hosts are exemplified by plasmids such as pDSR α described in WO90/14363. Expression vectors for bacterial host
10 cells are exemplified by plasmids pAMG21 and pAMG22-His described in WO97/23614. It is anticipated that the specific plasmids and host cells described are for illustrative purposes and that other available plasmids and host cells could also be used to express the polypeptides.

15 The invention also provides for expression of OPG from endogenous nucleic acids by in vivo or ex vivo recombination events. One strategy involves activation of a normally silent endogenous OPG gene by introduction of exogenous regulatory sequences (e.g.
20 promoters or enhancers) capable of directing the expression of OPG from the endogenous gene, or from a variant gene thereof which is present in the host genome or is generated by the introduction of exogenous sequences. Typically, exogenous sequences are carried
25 on vectors capable of homologous recombination with the host genome. In addition, endogenous or exogenous regulatory sequences capable of directing OPG production may be activated or stimulated to express OPG upon exposure to certain activating or stimulating
30 factors for transcription and/or translation.

OPG Pharmaceutical Compositions

OPG pharmaceutical compositions typically include a therapeutically effective amount of OPG
35 protein product in admixture with one or more pharmaceutically and physiologically acceptable

- 21 -

formulation materials. Suitable formulation materials include, but are not limited to, antioxidants, preservatives, coloring, flavoring and diluting agents, emulsifying agents, suspending agents, solvents, fillers, bulking agents, buffers, delivery vehicles, diluents, excipients and/or pharmaceutical adjuvants. For example, a suitable vehicle may be water for injection, physiological saline solution or other materials common in compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles.

The primary solvent in a vehicle may be either aqueous or non-aqueous in nature. In addition, the vehicle may contain other pharmaceutically-acceptable excipients for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the formulation. Similarly, the vehicle may contain still other pharmaceutically-acceptable excipients for modifying or maintaining the stability, rate of dissolution, or rate of release of OPG. Such excipients are those substances usually and customarily employed to formulate dosages for parenteral administration in either unit dose or multi-dose form.

Once the therapeutic composition has been formulated, it may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder. Such formulations may be stored either in a ready to use form or in a form, e.g., lyophilized, requiring reconstitution prior to administration.

The optimal pharmaceutical formulation will be determined by one skilled in the art depending upon the route of administration and desired dosage. See for example, *Remington's Pharmaceutical Sciences*, 18th

- 22 -

Ed. (1990, Mack Publishing Co., Easton, PA 18042) pages 1435-1712 the disclosure of which is hereby incorporated by reference.

Other effective administration forms, such as
5 parenteral slow-release formulations, inhalant mists, orally active formulations, or suppositories, are also envisioned. In one embodiment, OPG pharmaceutical compositions are formulated for parenteral administration. Such parenterally administered
10 therapeutic compositions are typically in the form of a pyrogen-free, parenterally acceptable aqueous solution comprising OPG in a pharmaceutically acceptable vehicle. One preferred vehicle is physiological saline.

15 Compositions for sustained release and/or delivery of OPG comprise OPG polypeptides modified with water soluble polymers as described above to increase solubility or stability. Compositions may also comprise incorporation of OPG into liposomes,
20 microemulsions, micelles or vesicles for controlled delivery over an extended period of time. Specifically, OPG compositions may comprise incorporation into polymer matrices such as hydrogels, silicones, polyethylenes, ethylene-vinyl acetate
25 copolymers, or biodegradable polymers. Examples of hydrogels include polyhydroxyalkylmethacrylates (p-HEMA), polyacrylamide, polymethacrylamide, polyvinylpyrrolidone, polyvinyl alcohol and various polyelectrolyte complexes. Examples of biodegradable
30 polymers include polylactic acid (PLA), polyglycolic acid (PGA), copolymers of PLA and PGA, polyamides and copolymers of polyamides and polyesters. Other controlled release formulations include microcapsules, microspheres, macromolecular complexes and polymeric
35 beads which may be administered by injection. Hylauronic acid may also be used, and this may have the

- 23 -

effect of promoting sustained duration in the circulation. Such compositions may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the present proteins and derivatives.

It is also contemplated that certain formulations containing OPG are to be administered orally. OPG which is administered in this fashion may be encapsulated and may be formulated with or without those carriers customarily used in the compounding of solid dosage forms. The capsule may be designed to release the active portion of the formulation at the point in the gastrointestinal tract when bioavailability is maximized and pre-systemic degradation is minimized. Additional excipients may be included to facilitate absorption. Diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents, and binders may also be employed.

20

Administration of OPG

OPG polypeptides may be administered parenterally via a subcutaneous, intramuscular, intravenous, transpulmonary, or transdermal route. To achieve the desired dose of OPG, repeated daily or less frequent injections may be administered. The frequency of dosing will depend on the pharmacokinetic parameters of the OPG polypeptide as formulated, and the route of administration.

Regardless of the manner of administration, the specific dose is typically calculated according to body weight or body surface area. Further refinement of the calculations necessary to determine the appropriate dosage for treatment involving each of the above mentioned formulations is routinely made by those of ordinary skill in the art, especially in light of

- 24 -

the dosage information and assays disclosed herein. Appropriate dosages may be ascertained through use of the established assays for determining dosages utilized in conjunction with appropriate dose-response data.

5 The final dosage regimen involved in a method of treating a specific condition will be determined by the attending physician, considering various factors which modify the action of drugs, e.g., the age, condition, body weight, sex and diet of the patient, the severity
10 of any infection, time of administration and other clinical factors. In one embodiment, the dose range for an Fc-OPG fusion protein, wherein the carboxy terminus of an Fc region is attached to the amino-terminal residue of a truncated OPG polypeptide (e.g.,
15 Fc-OPG [22-194]), is about 10 µg/kg to about 10 mg/kg.

OPG gene therapy in vivo is also envisioned wherein a nucleic acid sequence encoding OPG, a derivative thereof, or an OPG chimeric protein is introduced directly into the patient. For example, a
20 nucleic acid sequence encoding an OPG polypeptide is introduced into target cells via local injection of a nucleic acid construct with or without an appropriate delivery vector, such as an adeno-associated virus vector. Alternative viral vectors include, but are not
25 limited to, retrovirus, adenovirus, herpes simplex virus and papilloma virus vectors. Physical transfer may be achieved in vivo by local injection of the desired nucleic acid construct or other appropriate delivery vector containing the desired nucleic acid
30 sequence, liposome-mediated transfer, direct injection (naked DNA), receptor-mediated transfer (ligand-DNA complex), or microparticle bombardment (gene gun).

Atherosclerosis causes most degenerative
35 arterial disease and calcification of the arterial wall typically occurs in clinically significant lesions.

- 25 -

Narrowing and occlusion of the artery are the most common features of the disease although the strength of the arterial wall may also be compromised from loss of elastin and collagen. Consequences of arterial occlusion include dissection, aneurysms, ischemia, thrombosis, and acute and chronic cardiac diseases. In many instances, surgical or angioplastic treatments are required and, while effective, such treatments are necessarily invasive, do not prevent occlusion at other arterial sites, and in some cases may need to be repeated at the original sites (for example, in restenosis).

OPG may be used to prevent or treat atherosclerosis and Mockenberg's arteriosclerosis (medial calcific sclerosis), and other conditions characterized by arterial calcification. OPG may be administered alone or in combination with other drugs for treating atherosclerosis, such as anti-hypertensive drugs and cholesterol lowering drugs. Anti-hypertensive drugs include diuretics, α -adrenergic blocking drugs, β -adrenergic blocking drugs, calcium entry blocking drugs, angiotensin converting enzyme inhibitors and vasodilators. Cholesterol lowering drugs which reduce levels of low density lipoprotein (LDL) cholesterol include bile acid sequestrants, HMG-CoA reductase inhibitors, fibric acid derivatives and nicotinic acid. OPG may also be administered with anti-resorptive agents which may exhibit cardiovascular benefit, such as hormones (estrogens), vitamin D and vitamin D derivatives, and selective estrogen receptor modulators (SERMs), such as raloxifene (EVISTA). In addition, OPG may be administered in conjunction with surgical and angioplastic treatments, such as arterial prosthesis and ballon angioplasty.

- 26 -

The invention will be more fully understood by reference to the following examples. These examples are not to be construed in any way as limiting the scope of this invention.

5

EXAMPLE 1

OPG Expression analyzed by in situ hybridization

10 Preparation of embryos and tissues for in situ hybridization experiments and preparation of radioactively labeled oligonucleotide probes for detecting OPG mRNA levels have been described previously in Simonet et al. supra. Localization of
15 high levels of OPG mRNA in the incipient part of the aorta in 18.5 day mouse embryo is shown in Figure 1A - 1D. OPG expression in the adult rat is also apparent in the smooth muscle wall of the renal artery as shown in Figure 2A - 2E.

20

EXAMPLE 2

Preparation of OPG Knockout Mice

25 Procedures for preparing OPG Knockout Mice including construction of vectors for targeting OPG sequences to the mouse genome and introduction of said vectors into mouse embryos are described in co-pending and co-owned U.S. Serial No. 08/943,687 which is hereby
30 incorporated by reference.

- 27 -

EXAMPLE 3

Phenotypic Analysis of OPG Knockout Mice

Groups of homozygous OPG knockout mice (OPG^{-/-}), heterozygous knockout mice (OPG^{+/-}) and control mice (OPG^{+/+}) were necropsied at e18 and 7 day, 14 day, 60 day and 180 day postnatal. Radiography was performed prior to gross dissection. Serum from the mice was analyzed for clinical chemistries and full hematology. Total body and major organs were weighed and fixed in formalin.

A summary of the mice undergoing necropsy is shown in Table 1.

TABLE 1

Wild types (+/+)	Heterozgotes (+/-)	Homozygotes (-/-)
1-34 Male	1-28 Male	1-27 Male
1-37 Male	1-29 Male	1-26 Male ♦
1-45 Male	1-35 Male	1-38 Male ▼
1-25 Male	1-36 Male	77 Female
81 Female	1-46 Male	80 Female
82 Female	75 Female	86 Female
83 Female	76 Female	
	78 Female	

♦ OPG^{-/-} Mouse 1-26 was the runt of the litter, about half the size of a normal mouse. It became moribund and died shortly before the scheduled sacrifice, it displayed the signs of respiratory insufficiency shortly before dying. Blood for hematology and serum chemistries was drawn immediately after death by cardiac puncture and a regular necropsy was performed.

▼ OPG^{-/-} Mouse 1-38 was placed in one cage with OPG^{-/-} mouse 1-27 in preparation for the procedures and died within the last 1 hour prior to sacrifice, no blood

- 28 -

could be collected for testing. The rest of the autopsy was performed as usual and organs submitted for histology.

5 Analysis and results of bone morphology, histology and density, and hematology and serum chemistry parameters in OPG knockout mice have been reported in co-owned and copending U.S. Serial No. 08/943,687.

10 Two of the three male OPG ^{-/-} mice had arterial changes. In the heart of Mouse #26 extensive severe subendocardial calcinosis was present. Intimal proliferation and calcifications could be detected in the aorta (Figure 3A) and renal artery (Figure 3B).
15 Serum calcium was elevated to 11 versus 8.8±0.17 in the OPG ^{+/+} group. OPG ^{-/-} Mouse #38 - had intimal proliferation and subintimal chronic granulation tissue in the initial part of the aorta (Figure 3C) and in the renal artery (Figure 3D). Serum calcium value was not
20 available.

 Two of three female OPG ^{-/-} mice had calcifications and intimal proliferation in the aorta and renal artery (Figure 4B, 4C and 4D), serum calcium values were within the normal range. The third female
25 OPG ^{-/-} mouse displayed osteoporosis in the bone, had normal calcium levels and no arterial changes.

* * *

 While the present invention has been
30 described in terms of the preferred embodiments, it is understood that variations and modifications will occur to those skilled in the art. Therefore, it is intended that the appended claims cover all such equivalent variations which come within the scope of the invention
35 as claimed.

- 29 -

WHAT IS CLAIMED IS:

1. A method of treating or preventing cardiovascular disease comprising administering to a patient in need thereof a therapeutically effective amount of osteoprotegerin (OPG) in a pharmaceutical composition.
2. The method of Claim 1 wherein the cardiovascular disease is associated with atherosclerosis or Monckenberg's arteriosclerosis.
3. The method of Claim 1 further comprising administering a therapeutically effective amount of an anti-hypertensive drug.
4. The method of Claim 1 further comprising administering a therapeutically effective amount of a cholesterol-lowering drug.
5. The method of Claim 1 wherein osteoprotegerin is administered prior to, concurrent with, or after the onset of cardiovascular disease.
6. The method of Claim 1 wherein osteoprotegerin is administered in conjunction with surgical or angioplastic treatment.
7. The method of Claim 1 further comprising administration of an anti-resorptive agent selected from the group consisting of estrogens, vitamin D compounds and selective estrogen receptor modulators.
8. The method of Claim 1 wherein osteoprotegerin is a truncated OPG polypeptide.

- 30 -

9. The method of Claim 8 wherein the truncated polypeptide has up to about 216 amino acids deleted from the carboxy terminus as shown in SEQ ID
5 NO:2.

10. The method of Claim 1 wherein osteoprotegerin comprises a chimeric polypeptide comprising a truncated OPG polypeptide fused to an Fc
10 region from human IgG.

11. The method of Claim 12 wherein the carboxy terminus of the Fc region is fused to the amino terminus of the truncated OPG polypeptide.
15

12. The method of Claim 10 wherein the amino terminus of the Fc region is fused to the carboxy terminus of the truncated OPG polypeptide.

13. The method of Claim 9 wherein the truncated OPG polypeptide is a covalently linked multimer.
20

14. The method of Claims 11 or 12 wherein the truncated OPG polypeptide comprises residues 22-185,
25 22-189, 22-194, or 22-201 as shown in SEQ ID NO:2.

15. The method of Claim 1 wherein osteoprotegerin comprises residues 22-401 as shown in
30 SEQ ID NO:2.

16. The method of Claim 1 wherein a therapeutically effective amount of a nucleic acid encoding osteoprotegerin in a pharmaceutical
35 composition is administered to a patient in need thereof.

FIG.1A



FIG.1B



FIG.1C




FIG.1D




FIG.2A




FIG.2B




FIG.2C



FIG.2D



FIG.2E




FIG.3A



FIG.3B



FIG.3C



FIG.3D




FIG.4A




FIG.4B



FIG.4C



FIG.4D



SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Simonet, Scott
Sarosi, Ildiko
- (ii) TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE
PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Amgen Inc.
 - (B) STREET: One Amgen Center Drive
 - (C) CITY: Thousand Oaks
 - (D) STATE: California
 - (E) COUNTRY: USA
 - (F) ZIP: 91320-1789
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Winter, Robert B.
 - (C) REFERENCE/DOCKET NUMBER: A-525

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1355 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 94..1297
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GTATATATAA CGTGATGAGC GTACGGGTGC GGAGACGCAC CGGAGCGCTC GCCCAGCCGC	60
CGCTCCAAGC CCCTGAGGTT TCCGGGGACC ACA ATG AAC AAG TTG CTG TGC TGC	114
Met Asn Lys Leu Leu Cys Cys	
1 5	
GCG CTC GTG TTT CTG GAC ATC TCC ATT AAG TGG ACC ACC CAG GAA ACG	162
Ala Leu Val Phe Leu Asp Ile Ser Ile Lys Trp Thr Thr Gln Glu Thr	
10 15 20	
TTT CCT CCA AAG TAC CTT CAT TAT GAC GAA GAA ACC TCT CAT CAG CTG	210
Phe Pro Pro Lys Tyr Leu His Tyr Asp Glu Glu Thr Ser His Gln Leu	
25 30 35	

TTG TGT GAC AAA TGT CCT CCT GGT ACC TAC CTA AAA CAA CAC TGT ACA Leu Cys Asp Lys Cys Pro Pro Gly Thr Tyr Leu Lys Gln His Cys Thr 40 45 50 55	258
GCA AAG TGG AAG ACC GTG TGC GCC CCT TGC CCT GAC CAC TAC TAC ACA Ala Lys Trp Lys Thr Val Cys Ala Pro Cys Pro Asp His Tyr Tyr Thr 60 65 70	306
GAC AGC TGG CAC ACC AGT GAC GAG TGT CTA TAC TGC AGC CCC GTG TGC Asp Ser Trp His Thr Ser Asp Glu Cys Leu Tyr Cys Ser Pro Val Cys 75 80 85	354
AAG GAG CTG CAG TAC GTC AAG CAG GAG TGC AAT CGC ACC CAC AAC CGC Lys Glu Leu Gln Tyr Val Lys Gln Glu Cys Asn Arg Thr His Asn Arg 90 95 100	402
GTG TGC GAA TGC AAG GAA GGG CGC TAC CTT GAG ATA GAG TTC TGC TTG Val Cys Glu Cys Lys Glu Gly Arg Tyr Leu Glu Ile Glu Phe Cys Leu 105 110 115	450
AAA CAT AGG AGC TGC CCT CCT GGA TTT GGA GTG GTG CAA GCT GGA ACC Lys His Arg Ser Cys Pro Pro Gly Phe Gly Val Val Gln Ala Gly Thr 120 125 130 135	498
CCA GAG CGA AAT ACA GTT TGC AAA AGA TGT CCA GAT GGG TTC TTC TCA Pro Glu Arg Asn Thr Val Cys Lys Arg Cys Pro Asp Gly Phe Phe Ser 140 145 150	546
AAT GAG ACG TCA TCT AAA GCA CCC TGT AGA AAA CAC ACA AAT TGC AGT Asn Glu Thr Ser Ser Lys Ala Pro Cys Arg Lys His Thr Asn Cys Ser 155 160 165	594
GTC TTT GGT CTC CTG CTA ACT CAG AAA GGA AAT GCA ACA CAC GAC AAC Val Phe Gly Leu Leu Leu Thr Gln Lys Gly Asn Ala Thr His Asp Asn 170 175 180	642
ATA TGT TCC GGA AAC AGT GAA TCA ACT CAA AAA TGT GGA ATA GAT GTT Ile Cys Ser Gly Asn Ser Glu Ser Thr Gln Lys Cys Gly Ile Asp Val 185 190 195	690
ACC CTG TGT GAG GAG GCA TTC TTC AGG TTT GCT GTT CCT ACA AAG TTT Thr Leu Cys Glu Glu Ala Phe Phe Arg Phe Ala Val Pro Thr Lys Phe 200 205 210 215	738
ACG CCT AAC TGG CTT AGT GTC TTG GTA GAC AAT TTG CCT GGC ACC AAA Thr Pro Asn Trp Leu Ser Val Leu Val Asp Asn Leu Pro Gly Thr Lys 220 225 230	786
GTA AAC GCA GAG AGT GTA GAG AGG ATA AAA CGG CAA CAC AGC TCA CAA Val Asn Ala Glu Ser Val Glu Arg Ile Lys Arg Gln His Ser Ser Gln 235 240 245	834
GAA CAG ACT TTC CAG CTG CTG AAG TTA TGG AAA CAT CAA AAC AAA GCC Glu Gln Thr Phe Gln Leu Leu Lys Leu Trp Lys His Gln Asn Lys Ala 250 255 260	882
CAA GAT ATA GTC AAG AAG ATC ATC CAA GAT ATT GAC CTC TGT GAA AAC Gln Asp Ile Val Lys Lys Ile Ile Gln Asp Ile Asp Leu Cys Glu Asn 265 270 275	930
AGC GTG CAG CGG CAC ATT GGA CAT GCT AAC CTC ACC TTC GAG CAG CTT Ser Val Gln Arg His Ile Gly His Ala Asn Leu Thr Phe Glu Gln Leu 280 285 290 295	978
CGT AGC TTG ATG GAA AGC TTA CCG GGA AAG AAA GTG GGA GCA GAA GAC Arg Ser Leu Met Glu Ser Leu Pro Gly Lys Lys Val Gly Ala Glu Asp 300 305 310	1026

ATT GAA AAA ACA ATA AAG GCA TGC AAA CCC AGT GAC CAG ATC CTG AAG Ile Glu Lys Thr Ile Lys Ala Cys Lys Pro Ser Asp Gln Ile Leu Lys 315 320 325	1074
CTG CTC AGT TTG TGG CGA ATA AAA AAT GGC GAC CAA GAC ACC TTG AAG Leu Leu Ser Leu Trp Arg Ile Lys Asn Gly Asp Gln Asp Thr Leu Lys 330 335 340	1122
GGC CTA ATG CAC GCA CTA AAG CAC TCA AAG ACG TAC CAC TTT CCC AAA Gly Leu Met His Ala Leu Lys His Ser Lys Thr Tyr His Phe Pro Lys 345 350 355	1170
ACT GTC ACT CAG AGT CTA AAG AAG ACC ATC AGG TTC CTT CAC AGC TTC Thr Val Thr Gln Ser Leu Lys Lys Thr Ile Arg Phe Leu His Ser Phe 360 365 370 375	1218
ACA ATG TAC AAA TTG TAT CAG AAG TTA TTT TTA GAA ATG ATA GGT AAC Thr Met Tyr Lys Leu Tyr Gln Lys Leu Phe Leu Glu Met Ile Gly Asn 380 385 390	1266
CAG GTC CAA TCA GTA AAA ATA AGC TGC TTA T AACTGGAAAT GGCCATTGAG Gln Val Gln Ser Val Lys Ile Ser Cys Leu 395 400	1317
CTGTTTCCTC ACAATTGGCG AGATCCCATG GATGATAA	1355

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 401 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Asn Lys Leu Leu Cys Cys Ala Leu Val Phe Leu Asp Ile Ser Ile 1 5 10 15
Lys Trp Thr Thr Gln Glu Thr Phe Pro Pro Lys Tyr Leu His Tyr Asp 20 25 30
Glu Glu Thr Ser His Gln Leu Leu Cys Asp Lys Cys Pro Pro Gly Thr 35 40 45
Tyr Leu Lys Gln His Cys Thr Ala Lys Trp Lys Thr Val Cys Ala Pro 50 55 60
Cys Pro Asp His Tyr Tyr Thr Asp Ser Trp His Thr Ser Asp Glu Cys 65 70 75 80
Leu Tyr Cys Ser Pro Val Cys Lys Glu Leu Gln Tyr Val Lys Gln Glu 85 90 95
Cys Asn Arg Thr His Asn Arg Val Cys Glu Cys Lys Glu Gly Arg Tyr 100 105 110
Leu Glu Ile Glu Phe Cys Leu Lys His Arg Ser Cys Pro Pro Gly Phe 115 120 125
Gly Val Val Gln Ala Gly Thr Pro Glu Arg Asn Thr Val Cys Lys Arg 130 135 140
Cys Pro Asp Gly Phe Phe Ser Asn Glu Thr Ser Ser Lys Ala Pro Cys 145 150 155 160
Arg Lys His Thr Asn Cys Ser Val Phe Gly Leu Leu Leu Thr Gln Lys 165 170 175

Gly Asn Ala Thr His Asp Asn Ile Cys Ser Gly Asn Ser Glu Ser Thr
 180 185 190
 Gln Lys Cys Gly Ile Asp Val Thr Leu Cys Glu Glu Ala Phe Phe Arg
 195 200 205
 Phe Ala Val Pro Thr Lys Phe Thr Pro Asn Trp Leu Ser Val Leu Val
 210 215 220
 Asp Asn Leu Pro Gly Thr Lys Val Asn Ala Glu Ser Val Glu Arg Ile
 225 230 235 240
 Lys Arg Gln His Ser Ser Gln Glu Gln Thr Phe Gln Leu Leu Lys Leu
 245 250 255
 Trp Lys His Gln Asn Lys Ala Gln Asp Ile Val Lys Lys Ile Ile Gln
 260 265 270
 Asp Ile Asp Leu Cys Glu Asn Ser Val Gln Arg His Ile Gly His Ala
 275 280 285
 Asn Leu Thr Phe Glu Gln Leu Arg Ser Leu Met Glu Ser Leu Pro Gly
 290 295 300
 Lys Lys Val Gly Ala Glu Asp Ile Glu Lys Thr Ile Lys Ala Cys Lys
 305 310 315 320
 Pro Ser Asp Gln Ile Leu Lys Leu Leu Ser Leu Trp Arg Ile Lys Asn
 325 330 335
 Gly Asp Gln Asp Thr Leu Lys Gly Leu Met His Ala Leu Lys His Ser
 340 345 350
 Lys Thr Tyr His Phe Pro Lys Thr Val Thr Gln Ser Leu Lys Lys Thr
 355 360 365
 Ile Arg Phe Leu His Ser Phe Thr Met Tyr Lys Leu Tyr Gln Lys Leu
 370 375 380
 Phe Leu Glu Met Ile Gly Asn Gln Val Gln Ser Val Lys Ile Ser Cys
 385 390 395 400
 Leu

INTERNATIONAL SEARCH REPORT

International Application
PCT/US 99/08793

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 23614 A (AMGEN INC ; LACEY DAVID L (US); BOYLE WILLIAM J (US); CALZONE FRANK) 3 July 1997 (1997-07-03) page 4, line 13 - line 24; claims	1-16
P, Y	BUCA Y N ET AL: "osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification" GENES AND DEVELOPMENT, vol. 12, no. 9, 1 May 1998 (1998-05-01), pages 1260-1268, XP002090118 ISSN: 0890-9369 abstract page 1260, right-hand column - page 1261, left-hand column, paragraph 1 --- -/--	1-16

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 August 1999

Date of mailing of the international search report

22/09/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Seegert, K

INTERNATIONAL SEARCH REPORT

Internal Application
PCT/US 99/08793

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	SCHINKE T ET AL: "Molecular determinants of arterial calcification." ANNALS OF MEDICINE, (1998 DEC) 30 (6) 538-41. , XP002111833 "Arterial calcification in atherosclerosis" page 539	1-16
Y	PARHAMI F. ET AL: "Arterial calcification in face of osteoporosis in ageing: can we blame oxidized lipids" CURRENT OPINION IN LIPIDOLOGY, vol. 8, no. 5, 1997, pages 312-314, XP002111834 abstract	1-16
Y	DEMER L.L. : "A skeleton in the atherosclerosis closet" CIRCULATION, vol. 92, no. 8, 1995, pages 2029-2032, XP002111835 page 2030, right-hand column, paragraph 1	1-16
Y	BANKS L.M. ET AL: "Effect of degenerative spinal and aortic calcification on bone density measurements in post-menopausal women: links between osteoporosis and cardiovascular disease?" EUR. J. OF CLINICAL INVESTIGATION, vol. 24, no. 12, 1994, pages 813-817, XP002111836 abstract	1-16

INTERNATIONAL SEARCH REPORT

International Application
PCT/US 99/08793

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9723614 A	03-07-1997	AU 1468697 A	17-07-1997
		BG 101813 A	30-09-1998
		CA 2210467 A	03-07-1997
		CN 1182452 A	20-05-1998
		CZ 9702538 A	17-03-1999
		DE 19654610 A	26-06-1997
		EP 0784093 A	16-07-1997
		EP 0870023 A	14-10-1998
		FR 2742767 A	27-06-1997
		GB 2312899 A, B	12-11-1997
		HU 9801122 A	28-08-1998
		JP 11503616 T	30-03-1999
		NO 973699 A	21-10-1997
		NZ 326579 A	28-01-1999
		PL 321938 A	05-01-1998
		TR 970550 A	21-07-1997